Hashim Dasti

Hashim Dasti serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health under the Department of Health and Human Services. He manages a portfolio of research-supporting acquisitions critical to advancing scientific understanding of substance use disorders. His work centers on securing specialized laboratory equipment, diagnostic services, and analytical instrumentation to enable cutting-edge neurobiological and behavioral research. Dasti ensures compliance with federal acquisition regulations while aligning procurement decisions with NIDA’s mission to translate laboratory findings into clinical and public health applications, prioritizing technical rigor and scientific impact in all contracting actions. Dasti maintains strong, sustained relationships with leading academic and research institutions, including McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships reflect a preference for high-caliber research entities capable of delivering complex scientific services, including clinical trial support, neuroimaging analysis, and specialized diagnostic testing. His contracting patterns emphasize long-term, performance-based agreements that support multi-year research initiatives and collaborative science across institutional networks. His procurement strategy reflects minimal use of socioeconomic set-asides, with 97.3% of awards issued under full and open competition, indicating a primary focus on scientific merit and technical capability over socioeconomic criteria. While small business participation occurs at a modest 2.7% rate, it is targeted toward firms with demonstrated expertise in high-precision laboratory services and analytical instrumentation, ensuring alignment with research quality standards. Dasti’s primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 541380 (Testing Laboratories and Services), reflecting deep engagement with advanced scientific equipment and third-party analytical validation. He also regularly procures services under 811210 and 811219 for the maintenance and calibration of precision instruments, as well as 325413 for in-vitro diagnostic substances. His expertise spans the technical domains of neuropharmacology, biomarker analysis, and clinical research infrastructure, ensuring NIDA’s research ecosystem remains equipped with state-of-the-art capabilities.